Entera Bio (ENTX) Cash from Operations (2021 - 2026)

Entera Bio (ENTX) has reported Cash from Operations for 6 consecutive years, with 3090000.0 the latest figure, recorded in Q1 2026.

• Quarterly Cash from Operations fell 120.09% year-over-year to 3090000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9056000.0 (down 42.39% YoY) and the FY2025 annual result came in at 7370000.0, down 8.1% from the prior year.
• Cash from Operations slipped to 3090000.0 in Q1 2026 per ENTX's latest filing, from 1833000.0 in the prior quarter.
• Over the last five years, Cash from Operations for ENTX reached as high as 1335000.0 in Q2 2024 and fell as low as 4792000.0 in Q1 2022.
• A 5-year average of 2181588.24 and a median of 1862000.0 in 2024 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2023 — Cash from Operations soared 66.42% — and 2026, when it sank 120.09%.
• Year by year, Cash from Operations stood at 2011000.0 in 2022, then slumped by 30.13% to 2617000.0 in 2023, then soared by 43.94% to 1467000.0 in 2024, then slipped by 24.95% to 1833000.0 in 2025, then tumbled by 68.58% to 3090000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 3090000.0, 1833000.0, and 2502000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.